Thrombin Receptor Protease-Activated Receptor 4 Is a Key Regulator of Exaggerated Intimal Thickening in Diabetes Mellitus

Abstract

PAR-4 appears to play a hitherto unsuspected role in diabetic vasculopathy. The development of PAR-4 inhibitors might serve to limit mainly proliferative processes in restenosis-prone diabetic patients, particularly those patients in whom severe bleeding attributed to selective PAR-1 blockade or complete thrombin inhibition must be avoided or those who do not require anticoagulation.

References

Page 1

	Year	Citations
Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome Sonja I. Gringhuis, Tanja M. Kaptein, Brigitte A. Wevers, Nature Immunology InflammationNoncanonical Caspase-8 InflammasomeCytokineExtracellular Pathogen SensorMicrobial Pathogens	2012	598
PAR3 is a cofactor for PAR4 activation by thrombin Mayumi Nakanishi‐Matsui, Yaowu Zheng, David J. Sulciner, Nature ThrombopoiesisSignal TransductionNatural SciencesMolecular BiologyHemostasis	2000	547
Remodeling With Neointima Formation in the Mouse Carotid Artery After Cessation of Blood Flow Anjali Kumar, Volkhard Lindner Arteriosclerosis Thrombosis and Vascular Biology	1997	524
Protease-activated Receptors 1 and 4 Are Shut Off with Distinct Kinetics after Activation by Thrombin Michael J. Shapiro, Ethan J. Weiss, Tatjana R. Faruqi, Journal of Biological Chemistry ImmunologyProteasomeMolecular BiologyCellular PhysiologyThrombosis	2000	242
Posttranslational Modification of the AU-Rich Element Binding Protein HuR by Protein Kinase Cδ Elicits Angiotensin II-Induced Stabilization and Nuclear Export of Cyclooxygenase 2 mRNA Anke Doller, El‐Sayed Akool, Andrea Huwiler, Molecular and Cellular Biology EngineeringOxidative StressTranscriptional RegulationPosttranslational ModificationCox-2 Mrna Stability	2008	188
Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates Claudia K. Derian, Bruce P. Damiano, Andrew L. Darrow, Journal of Pharmacology and Experimental Therapeutics	2003	159
Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes Michelle L. O’Donoghue, Deepak L. Bhatt, Stephen D. Wiviott, Circulation	2011	149
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Shinya Goto, Hisashi Ogawa, M. Takeuchi, European Heart Journal	2010	146
Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats Patricia Andrade‐Gordon, Claudia K. Derian, Bruce E. Maryanoff, Journal of Pharmacology and Experimental Therapeutics	2001	112
The role of 3′-untranslated region (3′-UTR) mediated mRNA stability in cardiovascular pathophysiology Christine Misquitta, Vimala R. Iyer, Eva S. Werstiuk, Molecular and Cellular Biochemistry	2001	106

Page 1